Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $40.00 at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its target price cut by HC Wainwright from $75.00 to $40.00 in a research note released on Wednesday,Benzinga reports. They currently have a neutral rating on the biotechnology company's stock.

Several other research analysts have also recently commented on the stock. Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a report on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price for the company. Piper Sandler decreased their target price on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Morgan Stanley dropped their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC reduced their price objective on Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their target price for the company from $161.00 to $87.00 in a research note on Monday, March 31st. Six analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $131.22.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $0.25 during midday trading on Wednesday, reaching $36.27. The company's stock had a trading volume of 6,614,378 shares, compared to its average volume of 1,617,527. The company has a market cap of $3.56 billion, a price-to-earnings ratio of 29.02 and a beta of 0.85. Sarepta Therapeutics has a one year low of $35.46 and a one year high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a 50 day moving average price of $66.84 and a 200 day moving average price of $100.86.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The business's revenue was up 80.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.73 earnings per share. On average, equities research analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Vanguard Group Inc. boosted its holdings in Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after purchasing an additional 117,904 shares during the period. Capital International Investors lifted its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the period. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock worth $348,368,000 after buying an additional 285,100 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Sarepta Therapeutics by 0.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock valued at $237,901,000 after acquiring an additional 10,343 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Sarepta Therapeutics by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock valued at $207,538,000 after acquiring an additional 9,999 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.